IONIS PHARMACEUTICALS INC's ticker is IONS and the CUSIP is 462222100. A total of 350 filers reported holding IONIS PHARMACEUTICALS INC in Q3 2022. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $1,492,344 | +5.1% | 32,900 | -4.9% | 0.02% | +7.1% |
| Q2 2023 | $1,419,638 | +73.5% | 34,600 | +51.1% | 0.01% | +75.0% |
| Q1 2023 | $818,446 | -29.6% | 22,900 | -25.6% | 0.01% | -33.3% |
| Q4 2022 | $1,163,316 | -1.1% | 30,800 | +15.8% | 0.01% | -7.7% |
| Q3 2022 | $1,176,518 | +437.2% | 26,600 | +269.4% | 0.01% | +1200.0% |
| Q4 2021 | $219,000 | -44.1% | 7,200 | -38.5% | 0.00% | -75.0% |
| Q3 2021 | $392,000 | -38.4% | 11,700 | +18.2% | 0.00% | -42.9% |
| Q2 2019 | $636,000 | -49.4% | 9,900 | -36.1% | 0.01% | -53.3% |
| Q1 2019 | $1,258,000 | -0.2% | 15,500 | -33.5% | 0.02% | -11.8% |
| Q4 2018 | $1,260,000 | +12.1% | 23,300 | +6.9% | 0.02% | +30.8% |
| Q3 2018 | $1,124,000 | +23.8% | 21,800 | 0.0% | 0.01% | +18.2% |
| Q2 2018 | $908,000 | -5.5% | 21,800 | 0.0% | 0.01% | -8.3% |
| Q1 2018 | $961,000 | +238.4% | 21,800 | +289.3% | 0.01% | +300.0% |
| Q3 2017 | $284,000 | – | 5,600 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Sicart Associates LLC | 389,022 | $19,724,000 | 14.11% |
| BB BIOTECH AG | 7,861,934 | $398,600,000 | 11.03% |
| TANAKA CAPITAL MANAGEMENT INC | 62,101 | $3,149,000 | 7.02% |
| DOWLING & YAHNKE LLC | 675,891 | $34,268,000 | 3.48% |
| Asymmetry Capital Management, L.P. | 55,965 | $2,837,000 | 3.29% |
| Motley Fool Asset Management LLC | 259,000 | $13,131,000 | 2.63% |
| AXON CAPITAL LP | 49,500 | $2,510,000 | 2.09% |
| Opus Point Partners Management, LLC | 44,183 | $2,240,000 | 2.01% |
| Motley Fool Wealth Management, LLC | 332,007 | $16,833,000 | 1.43% |
| Bellevue Group AG | 265,706 | $13,469,000 | 1.41% |